Additionally, it should be noted that a wide range of relatively new agents, such as sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide-1 agonists, angiotensin receptor–neprilysin inhibitors, and aldosterone receptor antagonists, offer well-established CV and renal benefits in patients with T2DM or hypertension. Here, NR3C2 is linked to type 2 diabetes mellitus.